# Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

> **NCT05130970** · PHASE2 · COMPLETED · sponsor: **CSL Behring** · enrollment: 81 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Garadacimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05130970
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-03
- **Primary completion:** 2024-01-02
- **Final completion:** 2024-01-02
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05130970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05130970, "Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05130970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*